m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04335)
Name
IMX-942
Synonyms
IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex
    Click to Show/Hide
Status
Preclinical
TTD Drug ID
D02NEZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sequestosome-1 p62 (SQSTM1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sequestosome-1 p62 (SQSTM1) is a therapeutic target for IMX-942. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of IMX-942 through regulating the expression of Sequestosome-1 p62 (SQSTM1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sequestosome-1 p62 (SQSTM1) is a therapeutic target for IMX-942. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMX-942 through regulating the expression of Sequestosome-1 p62 (SQSTM1). [2], [3]
YTH domain-containing protein 1 (YTHDC1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sequestosome-1 p62 (SQSTM1) is a therapeutic target for IMX-942. The YTH domain-containing protein 1 (YTHDC1) has potential in affecting the response of IMX-942 through regulating the expression of Sequestosome-1 p62 (SQSTM1). [2], [4]
References
Ref 1 Autophagy of the m(6)A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis. Nat Commun. 2021 Apr 12;12(1):2183. doi: 10.1038/s41467-021-22469-6.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
Ref 3 The mechanism of m(6)A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by Beta-elemene. Cell Death Dis. 2020 Nov 11;11(11):969. doi: 10.1038/s41419-020-03148-8.
Ref 4 m(6)A reader YTHDC1 modulates autophagy by targeting SQSTM1 in diabetic skin. Autophagy. 2022 Jun;18(6):1318-1337. doi: 10.1080/15548627.2021.1974175. Epub 2021 Oct 17.